Novel antipsychotics in bipolar and schizoaffective mania.
OBJECTIVE
Novel antipsychotics are increasingly used in the treatment of bipolar and schizoaffective mania. This paper presents an overview of the controlled studies in this field.


METHODS
Using cross-references, a computerized search was performed on MEDLINE and EMBASE psychiatry covering the period 1990-2002.


RESULTS
Olanzapine and risperidone, added to mood stabilizers, and olanzapine as monotherapy enjoy the most evidential support in terms of efficacy and side-effect profile for their use in acute bipolar mania. The use of modern antipsychotics in bipolar prophylaxis and in both the short- and long-term treatment of schizomania has not been widely studied yet.


CONCLUSIONS
More controlled trials are still needed comparing modern antipsychotics as monotherapy and adjunctive to mood stabilizers with conventional antipsychotics, lithium, anticonvulsants and with each other in short-term and, especially, maintenance treatment of (schizo)mania. Partly based on controlled studies, olanzapine, risperidone and other modern antipsychotics could become preferable for these indications.
Mensink
G J R
GJ
Department of Psychotic Disorders, Mental Health Centre Drenthe, Assen, The Netherlands.
Slooff
C J
CJ
D014150:Antipsychotic Agents / Q000627:therapeutic use*; D001569:Benzodiazepines / Q000627:therapeutic use*; D001714:Bipolar Disorder / Q000188:drug therapy*; D006801:Humans; D000077152:Olanzapine; D011618:Psychotic Disorders / Q000188:drug therapy*; D018967:Risperidone / Q000627:therapeutic use*
D014150:Antipsychotic Agents; D001569:Benzodiazepines; D018967:Risperidone; D000077152:Olanzapine